He Cui-Yao, Qin Yan-Ran, Liu Cheng-Jun, Ren Jie, Fan Ji-Shan
Department of Pharmacy, Children's Hospital of Chongqing Medical University/Ministry of Education Key Laboratory of Child Development and Disorders/National Clinical Research Center for Child Health and Disorders (Chongqing)/China International Science and Technology Cooperation Base of Child Development and Critical Disorders/Chongqing Key Laboratory of Pediatrics, Chongqing 400014,
Zhongguo Dang Dai Er Ke Za Zhi. 2019 Sep;21(9):904-909. doi: 10.7499/j.issn.1008-8830.2019.09.012.
To investigate the effect of augmented renal clearance (ARC) on plasma concentration of vancomycin, bacteriological outcome, and clinical outcome in children with methicillin-resistant Staphylococcus aureus (MRSA) infection treated by vancomycin.
A retrospective analysis was performed for the clinical data of 60 critically ill children who were treated with vancomycin due to MRSA infection from January 2013 to July 2017 and underwent plasma concentration monitoring. According to estimated glomerular filtration rate, these children were divided into an ARC group with 19 children and a normal renal function group with 41 children. The two groups were compared in terms of the use of vancomycin, plasma concentration of vancomycin, and treatment outcome.
The children in the ARC group had an age of 1-12 years, and the ARC group had significantly higher body weight and body surface area than the normal renal function group (P<0.05). Compared with the normal renal function group, the ARC group had a significantly lower initial trough concentration of vancomycin and a significantly lower proportion of children who achieved the effective trough concentration of vancomycin (10-20 mg/L) (P<0.05). There were no significant differences in bacteriological outcome and clinical outcome between the two groups (P>0.05), but the ARC group had significantly longer length of stay in the pediatric intensive care unit (PICU) and length of hospital stay than the normal renal function group (P<0.05).
ARC can significantly reduce the trough concentration of vancomycin and prolong the length of PICU stay and the length of hospital stay in children with MRSA infection. Idividualized medication should be administered to children with ARC.
探讨肾脏清除率增加(ARC)对万古霉素治疗耐甲氧西林金黄色葡萄球菌(MRSA)感染患儿的血浆浓度、细菌学疗效及临床疗效的影响。
回顾性分析2013年1月至2017年7月因MRSA感染接受万古霉素治疗并进行血浆浓度监测的60例危重症患儿的临床资料。根据估计肾小球滤过率,将这些患儿分为ARC组19例和肾功能正常组41例。比较两组万古霉素的使用情况、万古霉素血浆浓度及治疗效果。
ARC组患儿年龄为1-12岁,ARC组患儿体重和体表面积显著高于肾功能正常组(P<0.05)。与肾功能正常组相比,ARC组万古霉素初始谷浓度显著降低,达到万古霉素有效谷浓度(10-20mg/L)的患儿比例显著降低(P<0.05)。两组细菌学疗效和临床疗效差异无统计学意义(P>0.05),但ARC组在儿科重症监护病房(PICU)的住院时间和住院总时间显著长于肾功能正常组(P<0.05)。
ARC可显著降低MRSA感染患儿万古霉素的谷浓度,延长PICU住院时间和住院总时间。对ARC患儿应实施个体化用药。